The listing of biologics on the PBS for IBD has not stopped the growth in use of 5-aminosalicylic acid compounds such as mesalazine, a Queensland study shows. Government expenditure on 5-aminosalicylic acid compounds increased by 173% from $33 million to $90.5 million between 2004 and 2015, an analysis of PBS figures shows. The dispensed amount ...
Biologics use in IBD pushes PBS costs to $250m a year
By Michael Woodhead
8 Feb 2018